Faculty

John A. Stauffer, M.D.

Clinical Studies

A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to evaluate the safety and effectiveness of the NanoKnife System for the ablation of unresectable Stage 3 pancreatic adenocarcinoma (Stage 3 pancreatic cancer).
Pancreatic Surgery Database (Pancreas Surgery database) Jacksonville, Fla.
The aims of this study will be collection of standard and routinely obtained data specifically in the preoperative evaluation, operative room, postoperative/hospitalization period, and long term follow from the electronic medical record. Data collected will then be analyzed with standard scientific methods.
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma (DIRECT) Jacksonville, Fla.
The purpose of this study is to evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC).

AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer Jacksonville, Fla.
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma (DIRECT) Rochester, Minn.
The purpose of this study is to evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC).